FDA rejects MAPS/Lykos MDMA therapy for PTSD
About this episode
On Aug 9th the FDA rejected the new drug application by Lykos (formerly MAPS PBC) for MDMA-assisted therapy for PTSD. This is disappointing news for those of us who were excited about the promising study results and eager to add MDMA-assisted therapy to the menu of treatment options for those suffering with PTSD. We discuss what appears to have influenced the FDA’s decision, the possible path forward for Lykos, how this ruling affects other companies trying to bring different psychedelic medicines to market, and much more.
Learn more about our podcast at https://numinusnetwork.com/learn/podcast/
Learn more about psychedelic therapy training opportunities at https://numinusnetwork.com/training/
Learn more about our clinical trials at https://www.numinusnetwork.com/research
Learn more about Numinus at https://numinusnetwork.com/
Email us at [email protected]
Follow us on Instagram:
https://www.instagram.com/drstevethayer/
https://www.instagram.com/innerspacedoctor/
https://www.instagram.com/numinushealth/
Get every episode summarized
Each time Psychedelic Therapy Frontiers publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Psychedelic Therapy Frontiers
The Loneliness Epidemic & the Healing Power of Connection | Psychedelic Therapy,...
Psychedelic Therapy Frontiers
New research on LSD for generalized anxiety and what’s helpful about a psilocybi...
Psychedelic Therapy Frontiers
What does “processing emotions” even mean?
Psychedelic Therapy Frontiers
I’m going through a really hard time. What can I do? (rebroadcast)
Psychedelic Therapy Frontiers